Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PRQR · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Proqr Therapeutics (PRQR) · oqro.io/stocks/PRQR · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.04−0.01 (−0.95%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Proqr Therapeutics is on record in SEC filings since 2006.
No open-market sale by an insider of Proqr Therapeutics (PRQR) was filed with the SEC in the last 90 days.
No trade in Proqr Therapeutics (PRQR) was disclosed by a member of Congress in the last 12 months.
Proqr Therapeutics's next results are expected on Mar 10, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−49.5% (−$1.02) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $2.06 on Nov 20, 2025 to $1.04 on Nov 20, 2026 (−49.5%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Leiden. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−49.5%
Market value
$110M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.89M shares sold short (2.7% of shares outstanding), −0.7% vs the previous count, 2.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last results
—
Next results, expected
Mar 10, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Proqr Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Proqr Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
No Schedule 13D or 13G filing on PRQR over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 5,000 words.
To date, we have financed our operations primarily through our initial public and follow-on offerings, and private placements of equity securities, convertible loans, licensing and research collaborations and to a lesser extent through funding from patient organizations and governmental bodies, such as Rijksdienst voor Ondernemend Nederland (“RVO”). In December 2022, the Company issued 9,381,586 shares to Lilly pursuant to the amended and restated licensing and research collaboration between the Company and Lilly, resulting in gross proceeds of € 14,122,000, with no significant transaction costs. In February 2023, ProQR also received an upfront payment of € 56,412,000.
And 19 more headings in the filing.
Source: SEC EDGAR, Form 20-F filed Mar 12, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
1 active phase 3 trial and 1 active phase 2 trial led by this company, mostly in leber congenital amaurosis 10, autosomal dominant retinitis pigmentosa.
2 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Off-exchange trading: 44.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (17.5% on ATS, 26.7% with other brokers), close to its 26-week average of 45.2%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: MS POOL (ATS-4) (15.1%), INSTINCT X (13.4%), INTELLIGENT CROSS LLC (10.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Against the S&P 500 over the year
Since Nov 18, 2025, PRQR is down 50.0% and the index fund is up 4.5%: 55 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much PRQR moves
Beta 1.8 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Latest annual report filed Mar 12, 2026, compared with the one filed Mar 13, 2025. Read the filing
Source: SEC EDGAR, Form 20-F filed Mar 12, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.